Alnylam – Early Assets (Pipeline) Global Medical Affairs Postdoctoral Research Fellow at Northeastern University in Boston, MA

Job description

About the Opportunity About the Opportunity Northeastern University Pharmaceutical Industry Fellowships Program is a two-year experiential program designed to advance lifelong learning and the education and training of Pharm.D. graduates. A key element of the program’s success is preparing Fellows to meet evolving workforce needs across various sectors of the pharmaceutical industry. Fellows have the opportunity to work closely with our innovative biopharmaceutical industry partners, while engaging with Northeastern University faculty in professional and career development, teaching, service, and scholarly activities. In partnership with Northeastern University, Alnylam Pharmaceuticals is offering a two-year Global Medical Affairs Early Assets fellowship, based in Cambridge, MA. About Alnylam We are the leader in RNAi therapeutics – a revolutionary approach with the potential to transform the lives of people with rare and common diseases. Built on Nobel Prize-winning science, Alnylam has delivered the breakthroughs that made RNAi therapeutics possible and are just at the beginning of what’s possible. Our deep pipeline, late-stage programs, and bold vision reflect our core values: fierce innovation, passion for excellence, purposeful urgency, open culture and commitment to people. We're proud to be a globally recognized top employer, where an authentic, inclusive culture and breakthrough thinking fuel one another. Our culture: Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we’ve been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine’s Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK – among others. At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law. Responsibilities The Early Assets Medical Affairs function develops the Medical strategy and leads Medical execution to support the development of Alnylam’s investigational RNAi therapeutics. Early Assets Medical Affairs partners with experts across the organization to guide each unique investigational program as it enters the clinic and throughout its Ph 1 through Ph 3 development. Working cross-functionally across U.S. and global teams, key activities include mapping the clinical landscape, fostering scientific engagement with key opinion leaders (KOLs) and other stakeholders, and supporting the dissemination of early clinical study results. Fellows can also expect to contribute to strategic medical planning, champion congress engagements, support the development of medical materials, and collaborate with leaders from other key internal partners. Functional Area • Lead therapeutic landscape and KOL mapping exercises to inform early program strategy, including supporting external engagement strategy and execution of a